News

US states and territories can now apply to the Centers for Disease Control and Prevention (CDC) for funds to fight Zika locally. The CDC said $25m in preparedness

Mylan will pay $950m in cash up front and up to $50m in future payments. The deal adds about 25 branded and generic products, a 25-product pipeline and

"We are very pleased to progress to the Phase 2 portion of this trial evaluating FPA008 as a treatment for patients with PVNS, an orphan joint disease associated

"These preliminary agreements in principle with the DOJ and the SEC represent an important step forward towards addressing the immediate issues facing Aegerion and positioning the Company for

The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational

In its written response, the FDA advised Tetraphase that data from one additional positive phase 3 clinical trial will be required to support a New Drug Application (NDA)

Under the settlement and license agreement, Horizon has granted Teligent the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under

The Phase 1 portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase 2 development. William Moore, Ph.D., Innocrin’s Chief Executive

Orphan drug designation provides certain exclusivity benefits, tax credits for certain research, longer exclusivity and a waiver of the New Drug Application user fee. The designation is made